Dr. Carol Nacy, founder and CEO, Sequella, Inc. is a recognized leader in the bioscience industry. She has been honored for her leadership in health care for her use of scientific research and preventive care to stem the spread of tuberculosis worldwide, and she was the recipient of Women in Bio’s “Special Outstanding Achievement Award” in 2007.

Sequella is a clinical-stage biopharmaceutical company focused on commercializing improved detection and treatments for infectious diseases of epidemic potential. Sequella recently received American Recovery and Reinvestment Act funds to continue the development of a new manufacturing technique for a promising new tuberculosis drug. Sequella's product portfolio also includes multifunctional targeted drug candidates with significant market opportunity in disease areas of known or suspected infectious etiology, such as systemic fungal infections, bacterial pneumonias, Crohn’s Disease and gastric ulcers.

Before founding Sequella, Dr. Nacy was Executive Vice President and Chief Scientific Officer of EntreMed from 1993 through its successful public offering in June of 1996. She is on the board of several companies and non-profits. She began her career as a Science Manager (GS-15) at the Walter Reed Army Institute of Research in Washington, D.C.